Intrexon Corp (XON) Expected to Post Earnings of -$0.31 Per Share

Brokerages predict that Intrexon Corp (NYSE:XON) will announce earnings per share (EPS) of ($0.31) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Intrexon’s earnings. The lowest EPS estimate is ($0.35) and the highest is ($0.24). Intrexon posted earnings of ($0.26) per share in the same quarter last year, which would indicate a negative year over year growth rate of 19.2%. The business is scheduled to report its next earnings report on Wednesday, March 7th.

On average, analysts expect that Intrexon will report full-year earnings of ($1.06) per share for the current financial year, with EPS estimates ranging from ($1.11) to ($0.99). For the next year, analysts expect that the firm will report earnings of ($0.87) per share, with EPS estimates ranging from ($1.00) to ($0.72). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Intrexon.

Intrexon (NYSE:XON) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.02. Intrexon had a negative return on equity of 18.68% and a negative net margin of 66.88%.

XON has been the topic of several recent research reports. JMP Securities reiterated an “outperform” rating and set a $42.00 price objective on shares of Intrexon in a research report on Thursday, October 5th. Griffin Securities reiterated a “buy” rating and set a $55.00 price objective on shares of Intrexon in a research report on Friday, October 6th. Northland Securities reiterated a “buy” rating and set a $27.00 price objective on shares of Intrexon in a research report on Friday, October 6th. Zacks Investment Research cut Intrexon from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. Finally, Stifel Nicolaus increased their price objective on Intrexon from $39.00 to $57.00 and gave the stock a “buy” rating in a research report on Friday, November 10th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $38.50.

A number of hedge funds have recently bought and sold shares of XON. Vanguard Group Inc. increased its position in shares of Intrexon by 3.4% in the second quarter. Vanguard Group Inc. now owns 4,433,879 shares of the biotechnology company’s stock worth $106,811,000 after purchasing an additional 147,517 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Intrexon by 5.6% in the second quarter. Goldman Sachs Group Inc. now owns 152,576 shares of the biotechnology company’s stock worth $3,675,000 after purchasing an additional 8,148 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Intrexon by 493.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,258 shares of the biotechnology company’s stock worth $271,000 after purchasing an additional 11,854 shares during the period. Virtu KCG Holdings LLC bought a new position in shares of Intrexon in the second quarter worth $593,000. Finally, Trellus Management Company LLC bought a new position in shares of Intrexon in the third quarter worth $475,000. Hedge funds and other institutional investors own 77.45% of the company’s stock.

Intrexon (XON) opened at $13.00 on Friday. The company has a current ratio of 2.05, a quick ratio of 1.85 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $1,570.00, a price-to-earnings ratio of -11.61 and a beta of 1.33. Intrexon has a 12-month low of $10.26 and a 12-month high of $26.99.

TRADEMARK VIOLATION NOTICE: This piece was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/21/intrexon-corp-xon-expected-to-post-earnings-of-0-31-per-share.html.

Intrexon Company Profile

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Get a free copy of the Zacks research report on Intrexon (XON)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intrexon (NYSE:XON)

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply